Alpa Laboratories (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
Alpa Laboratories Limited |
|||
Price: ₹114.49 | |||
52 Week Low: ₹69.90 52 Week High: ₹144.50 |
|||
Market Capital: 236.54 Crore (Smallcap) | |||
Healthcare -> Drug Manufacturers - Specialty & Generic |
Show Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Alpa Laboratories Share Price Target For 2024
- 1.1.1: Alpa Laboratories Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Alpa Laboratories Share Price Target For 2025
- 1.2.1: Alpa Laboratories Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Alpa Laboratories Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Alpa Laboratories Brief Company Overview
- 4: Alpa Laboratories Financial Performance
- 4.0.1: Is Alpa Laboratories A Good Buy For Long Term?
To predict the Alpa Laboratories's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Alpa Laboratories Share Price Target For 2024
The line chart displays the monthly closing prices of Alpa Laboratories with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Alpa Laboratories shares in 2024, see the table below.
Alpa Laboratories Share Price Target Table For 2024
Level | Value | Analysis |
---|---|---|
2024 Target 3 | 119.46 (+4.34%) | Price Action: 16 Sep 2024 Low |
2024 Target 2 | 118.22 (+3.25%) | Price Action: 13 Sep 2024 Low |
2024 Target 1 | 116.91 (+2.11%) | Price Action: 20 Sep 2024 High |
Current Price | 114.49 | Alpa Laboratories's share price as of 26 Dec 2024 |
Stop Loss 1 | 113.5 (-0.87%) | Price Action: 25 Nov 2024 High |
Stop Loss 2 | 112.3 (-1.92%) | Price Action: 08 Jan 2024 High |
Stop Loss 3 | 111.1 (-2.97%) | Price Action: Dec 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Alpa Laboratories is showing mixed momentum signals near key moving averages.
Key Technical Level: The 50-day moving average at ₹114.42 serves as the nearest technical reference point.
Historical Returns: 3-month: -17.75% | 6-month: +35.36% | 1-year: +10.83%
Alpa Laboratories Share Price Target For 2025
The line chart displays the monthly closing prices of Alpa Laboratories with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Alpa Laboratories shares in 2025, see the table below.
Alpa Laboratories Share Price Target Table For 2025
Level | Value | Analysis |
---|---|---|
2025 Target 3 | 166.84 (+45.72%) | Price Action: Chart |
2025 Target 2 | 163.73 (+43%) | Price Action: Chart |
2025 Target 1 | 162.11 (+41.59%) | Fibonacci Extension Level 123.60% |
Current Price | 114.49 | Alpa Laboratories's share price as of 26 Dec 2024 |
Stop Loss 1 | 99.65 (-12.97%) | Price Action: 07 Mar 2024 High |
Stop Loss 2 | 98.65 (-13.84%) | Price Action: 01 Feb 2024 Low |
Stop Loss 3 | 97.65 (-14.71%) | Price Action: 13 Feb 2024 Low |
Long-Term Technical Outlook
52-Week Range Analysis: Alpa Laboratories is currently trading at 59.8% of its 52-week range (₹69.9 - ₹144.5).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +10.83% | 3-year: +44.19% | 5-year: +577.46%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Alpa Laboratories Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
Year | Target 1 | Target 1 YoY Chg % | Target 2 |
---|---|---|---|
Current Price | ₹114.49 | ||
2024 | ₹111.17 | -2.89% | ₹112.84 |
2025 | ₹167.29 | +50.48% | ₹175.68 |
2026 | ₹227.90 | +36.23% | ₹231.32 |
2027 | ₹260.26 | +14.19% | ₹264.16 |
2028 | ₹270.20 | +3.81% | ₹291.39 |
2029 | ₹304.25 | +12.6% | ₹349.24 |
2030 | ₹382.93 | +25.86% | ₹407.10 |
2031 | ₹461.46 | +20.5% | ₹468.38 |
2032 | ₹481.61 | +4.36% | ₹488.83 |
2033 | ₹466.60 | -3.11% | ₹522.81 |
2034 | ₹497.32 | +6.58% | ₹580.66 |
2035 | ₹598.57 | +20.35% | ₹638.52 |
2036 | ₹695.01 | +16.11% | ₹705.44 |
2037 | ₹702.95 | +1.14% | ₹713.49 |
2038 | ₹663.00 | -5.68% | ₹754.23 |
2039 | ₹669.02 | +0.9% | ₹812.09 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Alpa Laboratories Brief Company Overview
Alpa Laboratories Limited: A Renowned Pharmaceutical Company Established in 1967, Alpa Laboratories Limited is a reputable pharmaceutical manufacturer based in India. The company specializes in producing and distributing a diverse range of pharmaceutical products for human...
and veterinary use. Key Products and Services: Ethical, generic, and over-the-counter products Injections, tablets, capsules, eye and ear drops, ointments, creams, and gels Anti-infectives, analgesics, and cardiovascular drugs Market Presence: Alpa Laboratories has a strong market presence in India, distributing its products through various channels including distributors, retail chemists, and hospitals. The company also exports its products to numerous countries across South America, Africa, Asia, Russia, Ukraine, and Kazakhstan. Commitment to Quality: Alpa Laboratories is committed to providing high-quality pharmaceutical products. The company adheres to stringent manufacturing standards and quality control measures to ensure the safety and efficacy of its products.Alpa Laboratories Financial Performance
Metric | Value | Description |
---|---|---|
Market Capital | 236.54 Crore | Market valuation of Alpa Laboratories's shares. |
Revenue (TTM) | 108.73 Crore | Total revenue generated by Alpa Laboratories over the past twelve months. |
Net Income (TTM) | +16.24 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
Operating Margin | -0.06% | Income from operations as a percentage of revenue, before taxes and interest. |
Profit Margin | +14.93% | Net income as a percentage of revenue, after all expenses. |
Revenue Growth (Quarterly) |
-15.7% | Change in revenue compared to the previous quarter. |
Earnings Growth (YOY Quarterly) |
+68% | Change in earnings compared to the same quarter last year. |
Debt-to-Equity (D/E) Ratio |
3.45 | Company's total debt divided by total shareholder equity. |
Total Debt | 5.24 Crore | Sum of Alpa Laboratories's current & long-term financial obligations. |
Total Cash | 92.85 Crore | Total amount of liquid funds available to Alpa Laboratories. |
Beta | 1.03 | Beta is greater than 1 indicating that the Alpa Laboratories's price is more volatile than the market. |
Is Alpa Laboratories A Good Buy For Long Term?
Alpa Laboratories, a small-cap stock with a market capitalization of ₹236.54 crore, shows strong growth potential. While Q1 2024-25 revenue decreased by 15.7% quarter-over-quarter, a healthy profit margin of 14.93% and significant year-over-year earnings growth of 68% are positive indicators. Impressive past performance—51.90% return in the last 12 months and 338.11% over five years—suggests considerable long-term potential. However, its small size introduces higher risk. Considering the data, Alpa Laboratories could be a good buy for long-term investors with a moderate to high-risk tolerance.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.